Roche Abandons Cholesterol Drug Trial on Poor Results

Roche is pulling the plug on the dal-Heart development program for its Phase III-stage CETP modulator dalcetrapib. The decision to end the program followed an independent data and safety monitoring bo…
Read the full story: BioSpace.com Featured News